Apolipoprotein E-ε2 and Resistance to Atherosclerosis in Midlife: The PESA Observational Study

BACKGROUND

APOE is a known genetic contributor to cardiovascular disease, but the differential role APOE alleles play in subclinical atherosclerosis remains unclear.

METHODS

The PESA (Progression of Early Subclinical Atherosclerosis) is an observational cohort study that recruited 4184 middle-aged asymptomatic individuals to be screened for cardiovascular risk and multiterritorial subclinical atherosclerosis. Participants were APOE-genotyped, and omics data were additionally evaluated.

RESULTS

In the PESA study, the frequencies for APOE -ε2, -ε3, and -ε4 alleles were 0.060, 0.844, and 0.096, respectively. This study included a subcohort of 3887 participants (45.8±4.3 years of age; 62% males). As expected, APOE-ε4 carriers were at the highest risk for cardiovascular disease and had significantly greater odds of having subclinical atherosclerosis compared with ε3/ε3 carriers, which was mainly explained by their higher levels of low-density lipoprotein (LDL)-cholesterol. In turn, APOE-ε2 carriers were at the lowest risk for cardiovascular disease and had significantly lower odds of having subclinical atherosclerosis in several vascular territories (carotids: 0.62 [95% CI, 0.47-0.81]; P=0.00043; femorals: 0.60 [0.47-0.78]; P=9.96×10-5; coronaries: 0.53 [0.39-0.74]; P=0.00013; and increased PESA score: 0.58 [0.48-0.71]; P=3.16×10-8). This APOE-ε2 atheroprotective effect was mostly independent of the associated lower LDL-cholesterol levels and other cardiovascular risk factors. The protection conferred by the ε2 allele was greater with age (50-54 years: 0.49 [95% CI, 0.32-0.73]; P=0.00045), and normal (<150 mg/dL) levels of triglycerides (0.54 [0.44-0.66]; P=4.70×10-9 versus 0.90 [0.57-1.43]; P=0.67 if ≥150 mg/dL). Omics analysis revealed an enrichment of several canonical pathways associated with anti-inflammatory mechanisms together with the modulation of erythrocyte homeostasis, coagulation, and complement activation in ε2 carriers that might play a relevant role in the ε2's atheroprotective effect.

CONCLUSIONS

This work sheds light on the role of APOE in cardiovascular disease development with important therapeutic and prevention implications on cardiovascular health, especially in early midlife.

REGISTRATION

URL: https://www.clinicaltrials.gov: NCT01410318.

Longitudinal interplay between subclinical atherosclerosis, cardiovascular risk factors, and cerebral glucose metabolism in midlife: results from the PESA prospective cohort study

BACKGROUND

Cardiovascular disease and dementia often coexist at advanced stages. Yet, longitudinal studies examining the interplay between atherosclerosis and its risk factors on brain health in midlife are scarce. We aimed to characterise the longitudinal associations between cerebral glucose metabolism, subclinical atherosclerosis, and cardiovascular risk factors in middle-aged asymptomatic individuals.

METHODS

The Progression of Early Subclinical Atherosclerosis (PESA) study is a Spanish longitudinal observational cohort study of 4184 asymptomatic individuals aged 40-54 years (NCT01410318). Participants with subclinical atherosclerosis underwent longitudinal cerebral [18F]fluorodeoxyglucose ([18F]FDG)-PET, and annual percentage change in [18F]FDG uptake was assessed (primary outcome). Cardiovascular risk was quantified with SCORE2 and subclinical atherosclerosis with three-dimensional vascular ultrasound (exposures). Multivariate regression and linear mixed effects models were used to assess associations between outcomes and exposures. Additionally, blood-based biomarkers of neuropathology were quantified and mediation analyses were performed. Secondary analyses were corrected for multiple comparisons using the false discovery rate (FDR) approach.

FINDINGS

This longitudinal study included a PESA subcohort of 370 participants (median age at baseline 49·8 years [IQR 46·1-52·2]; 309 [84%] men, 61 [16%] women; median follow-up 4·7 years [IQR 4·2-5·2]). Baseline scans took place between March 6, 2013, and Jan 21, 2015, and follow-up scans between Nov 24, 2017, and Aug 7, 2019. Persistent high risk of cardiovascular disease was associated with an accelerated decline of cortical [18F]FDG uptake compared with low risk (β=-0·008 [95% CI -0·013 to -0·002]; pFDR=0·040), with plasma neurofilament light chain, a marker of neurodegeneration, mediating this association by 20% (β=0·198 [0·008 to 0·740]; pFDR=0·050). Moreover, progression of subclinical carotid atherosclerosis was associated with an additional decline in [18F]FDG uptake in Alzheimer's disease brain regions, not explained by cardiovascular risk (β=-0·269 [95% CI -0·509 to -0·027]; p=0·029).

INTERPRETATION

Middle-aged asymptomatic individuals with persistent high risk of cardiovascular disease and subclinical carotid atherosclerosis already present brain metabolic decline, suggesting that maintenance of cardiovascular health during midlife could contribute to reductions in neurodegenerative disease burden later in life.

FUNDING

Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III, Santander Bank, Pro-CNIC Foundation, BrightFocus Foundation, BBVA Foundation, "la Caixa" Foundation.

Prognostic impact of right ventricular strain in isolated severe tricuspid regurgitation

Background

Right ventricular (RV) systolic function is determinant in the evaluation of patients with severe tricuspid regurgitation (TR). Timely detection of RV dysfunction with conventional 2D echocardiography is challenging. RV strain has emerged as an accurate and sensitive tool for evaluation of RV function with the capability of detecting subclinical RV dysfunction.

Purpose

This study was aimed to evaluate the prognostic value of RV strain parameters in consecutive stable patients with severe TR.

Methods

Consecutive patients in stable clinical status with at least severe TR (severe, massive or torrential TR) evaluated in the Heart Valve Clinic following a comprehensive clinical protocol were included. Patients with previous episodes of heart failure or scheduled for TV intervention were excluded. RV systolic function was measured with conventional echocardiographic indices (RV fractional area change [FAC], tricuspid annular plane systolic excursion [TAPSE], DTI S wave [`S]) and with Speckle-tracking echocardiography (STE) derived automatic peak global and free wall longitudinal strain (RV-GLS and RV-FWLS respectively) using the EPIQ system (Philips Medical Systems, Andover, Massachusetts). A combined endpoint of hospital admission due to heart failure (HF) or all-cause mortality was defined. The interobserver variability of RV strain was assessed in 20 randomly selected patients.

Results

A total of 176 patients were included in this study. Strain parameters detected higher percentage of RV dysfunction compared to conventional indices (figure 1). After a median follow-up of 28 months (IQR: 15–48 months), n=65 patients (37%) reached the combined endpoint. 65 (37%) were admitted for right heart failure and 8% of the population (n=14) died. Cumulative event-free survival was significantly worse in patients with impaired RV-GLS and RV-FWLS. Conventional indices of RV systolic function were not associated with outcomes (p&gt;0.05 for all). In a multivariable analysis (in a model including NYHA class, BNP values, biplane VC, RV end-diastolic area, and RV-FWLS), RV-FWLS was an independent predictors of heart failure and CV mortality (figure 1 and 2; LR χ2: 40.2, p&lt;0.001). Inter-observer agreements for RV strain values were high (intraclass correlation coefficient for RV-GLS and RV-FWLS, r=0.96 and r=0.98 respectively)

Conclusion

Clinical outcomes demonstrate that RV strain parameters are superior to conventional indices of RV function in patients with isolated ≥ severe TR and absence of previous episodes of heart failure. Among all parameters of RV function, RV-FWLS is the strongest independent predictor of mortality and HF.

Funding Acknowledgement

Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Instituto Carlos III

Cardiac magnetic resonance imaging derived reference values for ventricular anatomy and function and myocardial tissue characterization in adolescents: the EnIGMA study

Introduction

Cardiac magnetic resonance (CMR) imaging is a precise tool for the assessment of cardiac anatomy and function. However, studies providing reference values for CMR parameters, including myocardial tissue properties, in healthy adolescents are scarce.

Purpose

To provide CMR derived reference values for biventricular mass, volumes and function measured by cine steady-state free-precession (SSFP) sequences and myocardial tissue relaxation properties as measured by native T1- and T2-mapping sequences in healthy adolescents.

Methods

A comprehensive non-contrast CMR study was performed in healthy adolescents aged 15 to 18 years enrolled in the “Early ImaginG Markers of unhealthy lifestyles in Adolescents” (EnIGMA) project using a 3-Tesla CMR scanner between March 2021 and October 2021. The imaging protocol included a cine SSFP to provide high-quality images for chamber size and function analysis, and a T2-GraSE mapping and native T1-mapping sequences (MOLLI Scheme 5 (3) 3) to provide precise myocardial relaxation time properties. Images were analyzed by experienced observers using the Cardiac Analysis tool available at IntelliSpace Portal following a standard protocol. In cine SSFP sequences, right and left ventricles were manually contoured for end-diastolic and end-systolic phases in the short-axis orientation, respectively (Figure 1A, B). Native T1 and T2 maps were analyzed in a mid-ventricular short axis slice and summarized values per individual were determined (Figure 1C, D). Student's t-tests were used for between-gender comparisons.

Results

CMR scans were performed in 123 adolescents (63 girls, 51.2%) with a mean age of 16.0 years (standard deviation (SD)=0.5), mean body mass index of 21.4 (SD=3.2) kg/m2, mean body surface area of 1.69 (SD=0.16) m2, and mean heart rate during CMR acquisitions of 69 (SD=11) beats/minute. Reference percentiles (P) 3, 10, 25, 50, 75, 90 and 97 for the different parameters analyzed by gender are provided in Figure 2. Mean left and right ventricular end-diastolic indexed volumes were higher in boys than in girls (91.5 vs 78.1 ml/m2, p&lt;0.01; and 101.1 vs 84.2 ml/m2, p&lt;0.01), as well as the indexed cardiac mass (48.4 vs 36.4 g/m2, p&lt;0.01). Left ventricular ejection fraction (LVEF) was similar in boys and girls (62.0 vs. 62.9%, p=0.23), whereas right ventricular ejection fraction was slightly lower in boys than in girls (55.3 vs. 57.1%, p=0.03). Mean myocardial native T1 relaxation time was 1253 (SD=28) ms in girls and 1215 (SD=23) ms in boys (p&lt;0.01), whereas mean myocardial T2 relaxation time was 44.1 (SD=2.3) ms and 44.4 (SD=2.0) ms in girls and boys, respectively (p=0.46).

Conclusion

This study provided CMR derived reference values for biventricular anatomy, function, and myocardial tissue properties, in healthy adolescents aged 15 to 18 years. This information may be useful for the differential diagnosis of cardiac diseases, such as cardiomyopathies and myocarditis, in adolescent population.

Funding Acknowledgement

Type of funding sources: Public grant(s) – EU funding. Main funding source(s): Instituto de Salud Carlos III (ISCIII)-Fondo de Investigaciόn SanitariaEuropean Regional Development Fund/European Social Fund (“A way to make Europe”/“Investing in your future”)

Clinical utility and prognostic value of right atrial function in severe tricuspid regurgitation. One more piece of the puzzle

Background

Optimal management of severe tricuspid regurgitation (TR) remains controversial. While right ventricular systolic function is an established prognostic marker of outcomes, the potential role of right atrial (RA) function is unknown.

Purpose

This study was aimed to describe RA function by 2D speckle tracking echocardiography (STE) in severe TR and to evaluate its potential association with cardiovascular outcomes

Methods

Consecutive patients with at least severe TR (severe, massive or torrential TR) evaluated in the Heart Valve Clinic following a comprehensive clinical protocol were included. Consecutive control subjects and patients with permanent atrial fibrillation (AF) were included for comparison. RA function was measured with 2D-STE and 3 components of RA function were calculated: reservoir (RASr), conduit (RAScd) and contractile (RASct) RA values using an automatic 2D strain analytical software (AutoStrain, Philips Medical Systems the EPIQ system, Figure 1). A combined endpoint of hospital admission due to heart failure (HF) or all-cause mortality was defined. The interobserver variability of RA strain was assessed in 30 randomly selected subjects (20 TR+5 AF+5 controls).

Results

A total of 176 patients with severe TR, 20 AF patients and 20 controls subjects were included in this study. Patients with at least severe TR showed lower RASr and RAScd compared to controls and to AF patients (Figure 1 and Table 1, p&lt;0.05). After a median follow-up of 28 months (IQR: 15–48 months), n=65 patients with severe TR (37%) reached the combined endpoint. 65 (37%) were admitted for right heart failure and 8% of the population (n=14) died. Patients with events showed lower values of RASr and RAScd (p&lt;0.01 for both). Between both parameters RASr was more strongly associated with outcomes compared to RAScd (AUC 0.74 vs. 0.65, p&lt;0.01). RASr was an independent predictor of heart failure and all cause mortality adjusted by additional imaging prognostic parameters in a multivariable analysis (biplane vena contracta, RV end-diastolic area, and RV-free wall longitudinal strain [LR χ2: 49.7, p&lt;0.001]). RA area or volume was not associated with outcomes. A cut-off value of RASr of &lt;9.4% held the best accuracy to predict outcomes (adjusted HR 3.2 (1.81–5.84), p&lt;0.001, Figure 1). Inter-observer agreements for RA strain values across the whole cohort were high (intraclass correlation coefficient for RASr, RAScd and RASct, r=0.95, r=0.86, r=0,92 respectively)

Conclusions

Evaluation of RA function by 2D-STE is feasible, reproducible and is an independent predictor of heart failure and all-cause mortality in patients with at least severe TR.

Funding Acknowledgement

Type of funding sources: Public grant(s) – National budget only. Main funding source(s): INSTITUTO CARLOS III

The 4A classification for patients with tricuspid regurgitation

Background

Significant Tricuspid Regurgitation (TR) is associated with increased morbi-mortality. Clinical evaluation of TR patients is challenging.

Purpose

To establish a new clinical classification specific for patients with TR, the 4A classification, and evaluate its performance on prognosis.

Methods

Consecutive patients with isolated at least severe TR and absence of episodes of heart failure (HF) evaluated in the Heart Valve Clinic were included. Signs and symptoms of Asthenia, Ankle swelling, Abdominal pain or distention and/or Anorexia where registered, follow up was performed every 6 months. 4A classification ranged from A0 (no A) to A4 (three or four A's present). A combined endpoint of hospital admission due to right HF and cardiovascular mortality was defined.

Results

135 patients with significant TR between 2016 and 2021 were included (69% females, mean age was 78±7 years). During a median follow-up of 26 months (IQR: 10–41 months), n=53 patients (39%) reached the combined endpoint. 52 (38%) admitted for heart failure and 11% (n=15) died. At baseline 94% of patients were in NYHA I or II whereas 24% presented A2 or A3. The presence of A2 or A3 showed a high incidence of events (figure). The change in 4A class and GGT remained independent predictor of HF and cardiovascular mortality (adjusted HR per unit of change of 4A class 1.95 [1.37–2.77], p&lt;0.001)

Conclusions

For the first time, we show the use of a new clinical classification, specific for patients with TR based on signs and symptoms of right HF that is prognostic of events.

Funding Acknowledgement

Type of funding sources: None.

Non-contrast cardiac magnetic resonance imaging after SARS-CoV2 infection or vaccination in asymptomatic adolescents: insights from the EnIGMA study

Background

Myocarditis after SARS-CoV2 infection or vaccination is rare, but seems to be relatively more frequent in young population. Cardiac magnetic resonance (CMR) T2 weighted sequences have the potential to detect subclinical myocarditis. However, there is paucity of data on the potential myocardial involvement after SARS-CoV2 infection or vaccination in asymptomatic adolescents.

Purpose

To evaluate the presence of subclinical myocardial damage in adolescents who were infected with SARS-CoV2 or vaccinated against SARS-CoV2 using non-contrast CMR imaging.

Methods

Asymptomatic adolescents enrolled in the “Early ImaginG Markers of unhealthy lifestyles in Adolescents” (EnIGMA) project were scanned using a 3-Tesla CMR scanner between March 2021 and October 2021. CMR scans included CINE imaging and myocardial T2-mapping sequences. SARS-CoV2 IgG antibody testing was performed in capillary blood samples, and date of confirmed SARS-CoV2 infection and/or vaccination if any was collected. Participants were assigned to three different groups according to SARS-CoV2 status: Group 1 (non-infected and non-vaccinated), Group 2 (infected and non-vaccinated), and Group 3 (vaccinated, independently of past infection status). CMR images were analyzed by experienced observers blinded to adolescent's SARS-CoV2 status. ANOVA and multiple regression analysis, together with correlation coefficients, were used to study between-group differences and associations among variables of interest.

Results

A total of 115 adolescents with a mean age of 16.0 years (standard deviation (SD)=0.4), 54% girls, completed the CMR study and SARS-CoV2 data successfully, and were assigned to Group 1 (n=72), Group 2 (n=22), and Group 3 (n=21). Left and right ventricular ejection fraction (LVEF/RVEF) did not significantly differ among groups: mean LVEF was 62.8% (SD=4.1), 63.0% (SD=3.7) and 60.9% (SD=3.9) [p=0.12] and mean RVEF was 56.5% (SD=4.2), 56.5% (SD=5.5) and 54.5% (SD=5.1) [p=0.23] in Groups 1, 2 and 3, respectively. Similarly, there were no between-group significant differences in myocardial T2 relaxation values: mean T2 values were 44.1 ms (SD=2.2), 44.1 ms (SD=1.8) and 44.4 ms (SD=1.9) in Groups 1, 2, and 3, respectively (p=0.63) (Figure 1). No differences were found either after adjusting for age and gender. Median time (interquartile range) from date of infection or vaccination to CMR acquisition was 133 (121) days and 28 (38) days in Group 2 and Group 3, respectively. No correlation between time from infection/vaccination to CMR acquisition and T2 values was detected (Figure 2).

Conclusions

This observational study did not find evidence of subclinical myocardial involvement after SARS-CoV2 infection or vaccination in asymptomatic adolescents, as assessed with T2-mapping magnetic resonance imaging.

Funding Acknowledgement

Type of funding sources: Foundation. Main funding source(s): Instituto de Salud Carlos III (ISCIII)-Fondo de Investigaciόn Sanitaria.European Regional Development Fund/European Social Fund (“A way to make Europe”/“Investing in your future”.

STREI: a new index of right heart function in isolated severe tricuspid regurgitation by Speckle tracking Echocardiography

Background

Right ventricular (RV) performance is key in the management of patients with severe tricuspid regurgitation (TR); detection of RV dysfunction is crucial to identify on time patients that benefit from valve intervention. Conventional parameters of RV function by 2D echocardiography are influenced by changes on preload conditions and can remain unaffected until late stages of the disease. The right atrium (RA) has an important role in modulating RV filling and RA performance is impaired in severe TR. Potentially, an index that combines RV and RA function may reflect a broader view of the effects of severe TR in right heart function.

Purpose

1) to evaluate the clinical utility of combining RV and RA strain for prediction of CV outcomes and 2) to design a novel index by Speckle-tracking echocardiography (STREI index) that integrates RA and RV information

Methods

Consecutive patients with at least severe TR (severe, massive or torrential TR) evaluated in the Heart Valve Clinic following a comprehensive clinical protocol were included. Consecutive control subjects and patients with permanent atrial fibrillation (AF) were included for comparison. Reservoir RA strain (RASr) and RV-free wall longitudinal strain (RV-FWLS) analysis were performed using novel, automated 2D strain analytical software (AutoStrain, Philips Medical Systems the EPIQ system, Figure 1). Novel STREI index was calculated with the formula: [2 × RV-FWLS] + RASr in absolute numbers.

A combined endpoint of hospital admission due to heart failure (HF) or all-cause mortality was defined. The interobserver variability of RA strain was assessed in 30 randomly selected subjects (20 TR+5 AF+5 controls).

Results

A total of 176 patients with severe TR, 20 AF patients and 20 controls subjects were included in this study. Patients with TR showed lower STREI values compared to controls and to AF patients (TR vs. controls vs. AF: 55±18 vs. 116±12 vs. 70±13, p&lt;0,001). After a median follow-up of 28 months (IQR: 15–48 months), n=65 patients with severe TR (37%) reached the combined endpoint. Patients with both abnormal strains (abnormal RV-FWLS and abnormal RASr strain) showed a significantly higher rate of events (Figure 2A). In a multivariable analysis, STREI index was an independent predictor of HF and mortality adjusted by vena contracta, RV end-diastolic area, NYHA class and BNP values (LR χ2: 46,1, p&lt;0,001). A cut off value of STREI index &lt;50% held the best accuracy to predict outcomes. An abnormal STREI index was associated with 6,1-fold increased risk of HF or death (HR 6,9 (3,9–12,3), p&lt;0,001, Figure 2B) Inter-observer agreements for STREI values were high (intraclass correlation coefficient = 0,96).

Conclusion

STREI index is a feasible and reproducible new parameter of RV performance that independently predicts outcomes in patients with severe TR. Randomized studies should confirm its potential to identify those patients that benefit from earlier valve interventions.

Funding Acknowledgement

Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Instituto Carlos III

Effects of a comprehensive lifestyle intervention on cardiovascular health: the TANSNIP-PESA trial

Aims

To investigate the effectiveness of a 3-year worksite lifestyle intervention on cardiovascular metrics and to study whether outcomes are influenced by baseline subclinical atherosclerosis (SA) by non-invasive imaging.

Methods and results

A randomized controlled trial was performed to compare a lifestyle intervention with standard of care in asymptomatic middle-aged subjects, stratified by SA. The intervention consisted of nine motivational interviews during the first year, followed by three further sessions between Years 1 and 3. The primary outcome was the change in a pre-specified adaptation of the Fuster-BEWAT score (Blood pressure, Exercise, Weight, Alimentation, and Tobacco) between baseline and follow-up Years 1–3. A total of 1020 participants (mean age 50 ± 4 years) were enrolled, of whom 510 were randomly assigned to the intervention and 510 to the control group. The baseline adapted Fuster-BEWAT score was 16.2 ± 3.7 points in the intervention group and 16.5 ± 3.5 points in the control group. At Year 1, the score improved significantly in intervention participants compared with controls [estimate 0.83 (95% CI 0.52–1.15) points]. However, intervention effectiveness decreased to non-significant levels at Year 3 [0.24 (95% CI –0.10 to 0.59) points]. Over the 3-year period, the intervention was effective in participants having low baseline SA [0.61 (95% CI 0.30–0.93) points] but not in those with high baseline SA [0.19 (95% CI –0.26 to 0.64) points].

Conclusion

In middle-aged asymptomatic adults, a lifestyle intervention was associated with a significant improvement in cardiovascular health and behavioural metrics. The effect attenuated after 1 year as the intensity of the intervention was reduced.

Trial registration

ClinicalTrials.gov (NCT02561065).

Design of the β3-Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure Trial

•

CpcPH is a relatively common complication of chronic HF, is associated with poor survival, and has no specific pharmacological treatment.

•

ß3AR stimulation has shown improvement in pulmonary hemodynamics and RV performance in a translational large animal model mimicking this condition.

•

The SPHERE-HF trial is a Phase II randomized, double-blind clinical trial designed to evaluate the efficacy and safety of mirabegron (oral β3 AR agonist) in patients with CpcPH secondary to HF.

•

The SPHERE-HF trial will include 80 patients treated with mirabegron or placebo for 16 weeks.

•

The main outcome is the change in PVR. Secondary outcomes include changes in RV performance, clinical status, NT-proBNP levels, and additional pulmonary hemodynamic parameters.

Combined pre-and post-capillary hypertension (CpcPH) is a relatively common complication of heart failure (HF) associated with a poor prognosis. Currently, there is no specific therapy approved for this entity. Recently, treatment with beta-3 adrenergic receptor (β3AR) agonists was able to improve pulmonary hemodynamics and right ventricular (RV) performance in a translational, large animal model of chronic PH. The authors present the design of a phase II randomized clinical trial that tests the benefits of mirabegron (a clinically available β3AR agonist) in patients with CpcPH due to HF. The effect of β3AR treatment will be evaluated on pulmonary hemodynamics, as well as clinical, biochemical, and advanced cardiac imaging parameters. (Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure [SPHERE-HF]; NCT02775539)